Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism

Award Number: R01DK133448
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism - Project Summary/Abstract Fructose bisphosphate phosphatase (FBP1) is the rate-limiting enzyme in gluconeogenesis (GNG), whereas nuclear factor erythroid-related factor 2 encoded by the NFE2L2 gene (NRF2) is a transcription factor, previously identified as the master activator of the antioxidant defense response. NRF2 also activates the transcription of many metabolic genes, especially in liver. We found that Nrf2Act-HEP mice, in which NRF2 was selectively activated in hepatocytes, and fasted Fbp1ΔHEP mice, in which FBP1 was conditionally deleted in hepatocytes, exhibit similar metabolic phenotypes, including hypoglycemia, hepatomegaly, hepatosteatosis and hypertriglyceridemia, which are also manifested by insulin overdosed individuals and glucose- or carbohydrate-deprived FBP1-deficient children. Given these similarities, we asked whether NRF2 and FBP1 engage in biochemical crosstalk. Surprisingly, we found that hepatic activation of NRF2 induces FBP1 degradation, mediated by NRF2 induced EGF and PDGF expression, which through an autocrine signaling mechanism led to activation of ERK1/2 MAP kinases that phosphorylated FBP1 at serine 271 and triggered its ubiquitination and proteasomal degradation. Even more surprising was the finding that FBP1 expression led to inhibition of AKT, thereby relieving inhibitory phosphorylation of GSK3 isozymes, which phosphorylate a degron embedded within the NRF2 molecule and thereby induce its ubiquitin-dependent proteolysis. These findings led us to hypothesize that the NRF2-FBP1 crossregulatory loop is a key regulator of liver metabolism and homeostasis, whose aberrant function can promote liver damage and cancer. We plan to test this hypothesis through three specific aims: 1). Investigate the hypothesis that FBP1 induces NRF2 degradation in periportal hepatocytes by activating GSK3 or enhancing its recruitment to NRF2; 2). Determine whether NRF2 activation alters liver zonation and contributes to the metabolic defects caused by FBP1 ablation; 3). Investigate whether NRF2-induced FBP1 degradation or NRF2 upregulation control the progression from chronic metabolic stress to hepatocellular carcinoma. Pursuing these aims via new mouse models, cell biological studies and highly innovative Seq-Scope technology, which we had developed for high-content spatial transcriptomic and proteomic profiling of single liver cells, will answer several critical questions of general importance: 1). What are the non-enzymatic mechanisms through which FBP1 has a broad effect on liver metabolism beyond its well-studied involvement in GNG? 2). What is the role of NRF2 in the metabolic alterations caused by FBP1 deficiency? 3). What is the role of a previously described FBP1- aldolase B interaction in AKT inhibition and GSK3-induced NRF2 degradation? and 4). What is the role of AKT activation in the metabolic defects and increased susceptibility to oncogenic transformation exhibited by the FBP1-deficient liver?


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $142,830 )
2026	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	4	2/20/2026	NON-COMPETING CONTINUATION	$28,980
2026	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	006	4	4/8/2026	NON-COMPETING CONTINUATION	$1
2026	2025	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	005	5	4/3/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$1
2026	2025	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	5	1/28/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$537,674
2026	2025	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	004	5	4/1/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1
2026	2025	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	5	2/20/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$28,982
2026	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	1/28/2026	NON-COMPETING CONTINUATION	-$394,843
														Subtotal = $142,830

Issue Date FY: 2025 ( Subtotal = $670,983 )
2025	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	6/13/2025	NON-COMPETING CONTINUATION	$670,983
														Subtotal = $670,983

Issue Date FY: 2024 ( Subtotal = $650,734 )
2024	2024	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	5/17/2024	NON-COMPETING CONTINUATION	$650,734
														Subtotal = $650,734

Issue Date FY: 2023 ( Subtotal = $684,436 )
2023	2023	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DRIVE	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	6/2/2023	NON-COMPETING CONTINUATION	$684,436
														Subtotal = $684,436

Issue Date FY: 2022 ( Subtotal = $705,251 )
2022	2022	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/25/2022	NEW	$705,251
														Subtotal = $705,251

Grand Total All Awards = $2,854,234

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism

Award Number: R01DK133448

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer